Market Overview

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023

Share:

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023

PR Newswire

NEW YORK, July 30, 2018 /PRNewswire/ -- Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis

Read the full report: https://www.reportlinker.com/p04890882

Report Details
The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 196-page report you will receive 141 charts– all unavailable elsewhere.
The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

Submarket forecasts from 2018-2028:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

Revenue forecast from 2018-2028 for 17 leading products:
• Humira
• Remicade
• Lialda
• Asacol
• Pentasa
• Xifaxan
• Cimzia
• Tysabri
• Simponi
• Canasa/Salofalk
• Entyvio
• Apriso
• Medrol
• Neoral
• Entocort
• Uceris
• Azulfidine

Revenue forecasts from 2018-2028 for 11 countries:
• US
Japan
Germany, France, UK, Spain and Italy (EU5)
Brazil, Russia, India and China (BRIC)

Discussions on research and development, including drug candidates in these classes: 
• Interleukin (IL) inhibitors 
• Cell-adhesion molecule (CAM) inhibitors 
• TNF-alpha inhibitors 
• Stem cell therapies 
• JAK inhibitors 
• Toll-like receptor agonists 
• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry 
• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market. 
 

Read the full report: https://www.reportlinker.com/p04890882

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-inflammatory-bowel-diseases-ibd-drug-market-is-estimated-at-6-7bn-in-2017-and-7-6bn-in-2023--300688523.html

SOURCE Reportlinker

View Comments and Join the Discussion!